Artelo Biosciences grants options to director

ARTELO BIOSCIENCES, INC. reported that director Steven Kelly received a grant of stock options for 136 shares of common stock at an exercise price of $1.15 per share.

Rhea-AI Filing Summary

ARTELO BIOSCIENCES, INC. reported that director Steven Kelly received a grant of stock options for 136 shares of common stock at an exercise price of $1.15 per share. The options vest 100% on the earlier of the one-year anniversary of a July 17, 2026 vesting commencement date or the day prior to the next annual stockholder meeting following that date, subject to continued service as a Service Provider, and expire on 2036-07-17.

Insider Trade Summary

Grant/Award: 136 shares

Grant/Award 1 txn

Insider Kelly Steven

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	136	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 136 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.

Key Figures

Options granted: 136 shares Exercise price: $1.1500 per share Expiration date: 2036-07-17 +3 more

6 metrics

Options granted 136 shares Stock option grant to director Steven Kelly

Exercise price $1.1500 per share Exercise price of the stock option award

Expiration date 2036-07-17 Stock option expiration date

Underlying shares 136 shares Common shares underlying the option grant

Vesting percentage 100% Portion of option that vests on the specified vesting date

Vesting Commencement Date July 17, 2026 Date from which vesting schedule is measured

Key Terms

Stock Option (right to buy), Vesting Commencement Date, Service Provider

3 terms

Stock Option (right to buy) financial

"security titled Stock Option (right to buy) for 136 shares"

Vesting Commencement Date financial

"Vesting Commencement Date" shall mean July 17, 2026."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Steven Kelly report for ARTL?

Director Steven Kelly reported receiving a grant of stock options for 136 shares of Artelo Biosciences common stock at an exercise price of $1.15 per share. The award is a compensation-related acquisition rather than a market purchase or sale.

What are the vesting terms of Steven Kelly’s ARTL stock options?

The options vest 100% if Kelly continues as a Service Provider through the applicable vesting date. Vesting occurs on the earlier of the one-year anniversary of the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholder meeting following that date.

What is the exercise price and expiration date of the ARTL options granted?

The stock options have an exercise price of $1.15 per share and expire on 2036-07-17. They cover 136 underlying common shares, which may be purchased upon exercise after vesting, subject to the grant’s terms.

Is Steven Kelly’s ARTL option grant a direct or indirect holding?

The Form 4 reports the option grant as a direct holding of Steven Kelly. Following the transaction, his directly held derivative position from this grant is shown as 136 options corresponding to 136 underlying shares of common stock.

Was Steven Kelly’s ARTL option grant made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox was not selected, indicating this grant is not reported as made under a pre-arranged 10b5-1 trading plan. It is disclosed as a compensation-related option award with specified vesting and expiration terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/21/2026 - 06:25 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelly Steven

(Last) (First) (Middle)

C/O ARTELO BIOSCIENCES, INC.

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.15	07/17/2026		A		136		(1)	07/17/2036	Common Stock	136	$0.00	136	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.

	/s/ Gregory D. Gorgas, as Attorney-in-Fact	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)